Collect

      

Specimen Preparation

 

  1. Perform lumbar puncture and discard the first 2mL of cerebrospinal fluid (CSF).
  2. Using the gravity drip method, collect at least 2.5 mL of CSF directly into a low-bind polypropylene false bottom CSF tube (provided in collection kit).

    Avoid syringes or tubing to prevent loss of Abeta42 with exposure to plastics. 

  3. Place CSF sample within foam insert and biohazard bag in the transport kit.


    Note: If the kit is being shipped, cold pack should be frozen ahead of CSF collection to ensure acceptable transport conditions.

Specimen

CSF

Unacceptable Conditions

Specimens not submitted in low-bind polypropylene false bottom CSF tube.

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio

Stability

15° to 25°C: 5 days; 2° to 8°C: 2 weeks; Frozen: 8 weeks

Storage/Transport Temperature

Refrigerated: 2° to 8°C

Synonyms

  • LAB8522
  • Alzheimer's
  • Alzheimer's Disease Biomarkers
  • LAB8522VML
  • Alzheimer’s Disease Biomarker Panel, CSF

Performed

Tuesday and Friday

Performing Lab

VML MetroCenter

Ordering Indicators

Testing is intended to evaluate for Alzheimer's disease (AD) and other causes of cognitive impairment in adult patients aged 55 years and older.

Interpretive Data

pTau181/Abeta42 RatioInterpretation
≤ 0.023 A negative result consistent with a negative amyloid PET scan result.
> 0.023 A positive result consistent with a positive amyloid PET scan result.
 tTau/Abeta42 RatioInterpretation
≤ 0.28 A negative result consistent with a negative amyloid PET scan result.
> 0.28 A positive result consistent with a positive amyloid PET scan result.

Reference Interval

pTau181/Abeta42 Ratio: ≤ 0.023
tTau/Abeta42 Ratio: ≤ 0.28

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.

Section

Chemistry

CPT Codes

82234, 84393, 84394

Collect

      

Specimen Preparation

 

  1. Perform lumbar puncture and discard the first 2mL of cerebrospinal fluid (CSF).
  2. Using the gravity drip method, collect at least 2.5 mL of CSF directly into a low-bind polypropylene false bottom CSF tube (provided in collection kit).

    Avoid syringes or tubing to prevent loss of Abeta42 with exposure to plastics. 

  3. Place CSF sample within foam insert and biohazard bag in the transport kit.


    Note: If the kit is being shipped, cold pack should be frozen ahead of CSF collection to ensure acceptable transport conditions.

Unacceptable Conditions

Specimens not submitted in low-bind polypropylene false bottom CSF tube.

Storage/Transport Temperature

Refrigerated: 2° to 8°C

Performed

Tuesday and Friday

Stability

15° to 25°C: 5 days; 2° to 8°C: 2 weeks; Frozen: 8 weeks

Specimen

CSF

Ordering Indicators

Testing is intended to evaluate for Alzheimer's disease (AD) and other causes of cognitive impairment in adult patients aged 55 years and older.

Synonyms

  • LAB8522
  • Alzheimer's
  • Alzheimer's Disease Biomarkers
  • LAB8522VML
  • Alzheimer’s Disease Biomarker Panel, CSF

Performed

Tuesday and Friday

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio

Reference Interval

pTau181/Abeta42 Ratio: ≤ 0.023
tTau/Abeta42 Ratio: ≤ 0.28

Interpretive Data

pTau181/Abeta42 RatioInterpretation
≤ 0.023 A negative result consistent with a negative amyloid PET scan result.
> 0.023 A positive result consistent with a positive amyloid PET scan result.
 tTau/Abeta42 RatioInterpretation
≤ 0.28 A negative result consistent with a negative amyloid PET scan result.
> 0.28 A positive result consistent with a positive amyloid PET scan result.

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.

CPT Codes

82234, 84393, 84394

Performing Lab

VML MetroCenter

Section

Chemistry

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio
Full View

Collect

      

Specimen Preparation

 

  1. Perform lumbar puncture and discard the first 2mL of cerebrospinal fluid (CSF).
  2. Using the gravity drip method, collect at least 2.5 mL of CSF directly into a low-bind polypropylene false bottom CSF tube (provided in collection kit).

    Avoid syringes or tubing to prevent loss of Abeta42 with exposure to plastics. 

  3. Place CSF sample within foam insert and biohazard bag in the transport kit.


    Note: If the kit is being shipped, cold pack should be frozen ahead of CSF collection to ensure acceptable transport conditions.

Specimen

CSF

Unacceptable Conditions

Specimens not submitted in low-bind polypropylene false bottom CSF tube.

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio

Stability

15° to 25°C: 5 days; 2° to 8°C: 2 weeks; Frozen: 8 weeks

Storage/Transport Temperature

Refrigerated: 2° to 8°C

Synonyms

  • LAB8522
  • Alzheimer's
  • Alzheimer's Disease Biomarkers
  • LAB8522VML
  • Alzheimer’s Disease Biomarker Panel, CSF

Performed

Tuesday and Friday

Performing Lab

VML MetroCenter

Ordering Indicators

Testing is intended to evaluate for Alzheimer's disease (AD) and other causes of cognitive impairment in adult patients aged 55 years and older.

Interpretive Data

pTau181/Abeta42 RatioInterpretation
≤ 0.023 A negative result consistent with a negative amyloid PET scan result.
> 0.023 A positive result consistent with a positive amyloid PET scan result.
 tTau/Abeta42 RatioInterpretation
≤ 0.28 A negative result consistent with a negative amyloid PET scan result.
> 0.28 A positive result consistent with a positive amyloid PET scan result.

Reference Interval

pTau181/Abeta42 Ratio: ≤ 0.023
tTau/Abeta42 Ratio: ≤ 0.28

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.

Section

Chemistry

CPT Codes

82234, 84393, 84394
Specimen Requirements

Collect

      

Specimen Preparation

 

  1. Perform lumbar puncture and discard the first 2mL of cerebrospinal fluid (CSF).
  2. Using the gravity drip method, collect at least 2.5 mL of CSF directly into a low-bind polypropylene false bottom CSF tube (provided in collection kit).

    Avoid syringes or tubing to prevent loss of Abeta42 with exposure to plastics. 

  3. Place CSF sample within foam insert and biohazard bag in the transport kit.


    Note: If the kit is being shipped, cold pack should be frozen ahead of CSF collection to ensure acceptable transport conditions.

Unacceptable Conditions

Specimens not submitted in low-bind polypropylene false bottom CSF tube.

Storage/Transport Temperature

Refrigerated: 2° to 8°C

Performed

Tuesday and Friday

Stability

15° to 25°C: 5 days; 2° to 8°C: 2 weeks; Frozen: 8 weeks

Specimen

CSF
Ordering

Ordering Indicators

Testing is intended to evaluate for Alzheimer's disease (AD) and other causes of cognitive impairment in adult patients aged 55 years and older.

Synonyms

  • LAB8522
  • Alzheimer's
  • Alzheimer's Disease Biomarkers
  • LAB8522VML
  • Alzheimer’s Disease Biomarker Panel, CSF

Performed

Tuesday and Friday

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio
Results Interpretation

Reference Interval

pTau181/Abeta42 Ratio: ≤ 0.023
tTau/Abeta42 Ratio: ≤ 0.28

Interpretive Data

pTau181/Abeta42 RatioInterpretation
≤ 0.023 A negative result consistent with a negative amyloid PET scan result.
> 0.023 A positive result consistent with a positive amyloid PET scan result.
 tTau/Abeta42 RatioInterpretation
≤ 0.28 A negative result consistent with a negative amyloid PET scan result.
> 0.28 A positive result consistent with a positive amyloid PET scan result.

Methodology

Roche Electrochemiluminescent Immunoassay

Results obtained with different assay methods or kits may result in significantly different ratios and cannot be used interchangeably.
Additional Information

CPT Codes

82234, 84393, 84394

Performing Lab

VML MetroCenter

Section

Chemistry

Components

Phospho-Tau (181)/Abeta42 Ratio, Total-Tau/Abeta42 Ratio

Ordering Info

Collect
      
Synonyms
  • LAB8522
  • Alzheimer's
  • Alzheimer's Disease Biomarkers
  • LAB8522VML
  • Alzheimer’s Disease Biomarker Panel, CSF

×
Learn More Remind Me Later Dismiss